Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
RDEA3170 5 mg
DRUG
2 trials
Sponsors
Ardea Biosciences, Inc.
Conditions
Gout
Phase 2
RDEA3170 Monotherapy in Subjects With Gout
Completed
NCT01927198
Ardea Biosciences, Inc.
Gout
Start: 2013-08-31
End: 2014-07-31
Updated: 2015-07-01
RDEA3170 and Febuxostat Combination Study in Gout Subjects
Completed
NCT02246673
Ardea Biosciences, Inc.
Gout
Start: 2014-10-31
End: 2016-02-29
Updated: 2017-07-27
Related Papers
Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.
2020-09-19
5 citations
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials
Modern Rheumatology
2018-10-18
50 citations
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
RMD Open
2018-04-01
13 citations
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
RMD Open
2018-02-01
39 citations